A study of immunohistochemical differential expression in pulmonary and mammary carcinomas

Modern Pathology

Volumn 23, Issue 5, 2010, Pages 654-661

  Yang, Michael ^a   Nonaka, Daisuke ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast; Estrogen receptor; Lung; Metastasis; Napsin A; TTF 1

Indexed keywords

BIOLOGICAL MARKER; ESTROGEN RECEPTOR; MAMMAGLOBIN; NAPSIN A; PROTEIN GCDFP 15; SURFACTANT APOPROTEIN A; THYROID TRANSCRIPTION FACTOR 1; TRANSCRIPTION FACTOR GATA 3; UNCLASSIFIED DRUG;

ARTICLE; BREAST CARCINOMA; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG METASTASIS; LUNG SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOCARCINOMA; ASPARTIC ACID ENDOPEPTIDASES; BREAST NEOPLASMS; CARCINOMA, SQUAMOUS CELL; DIAGNOSIS, DIFFERENTIAL; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; NEOPLASMS, SECOND PRIMARY; TUMOR MARKERS, BIOLOGICAL;

EID: 77952011329     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2010.38     Document Type: Article

References (66)

1. Wang MP, Zee S, Zarbo RJ. Coordinate expression of cytokeratin 7 and 20 defines unique subsets of carcinomas. Appl Immunohistochem 1995;3:199-107.
2. Tavassoli FA, Devilee P. Tumours of the breast In: Tavassoli FA, Devilee P (eds). Tumours of the Breast and Female Genital Organs. IARC Press: Lyon, France, 2003, pp 9-112.
3. Travis WD, Brambilla E, Müller-Hermelink HK, et al. Tumours of the lung. In: Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC (eds). Tumours of the Lung, Pleura, Thymus and Heart. IARC Press: Lyon, France, 2004, pp 9-124.
4. Tanaka H, Tsukuma H, Koyama H, et al. Second primary cancers following breast cancer in the Japanese female population. Jpn J Cancer Res 2001;92:1-8.
5. Prochazka M, Granath F, Ekbom A, et al. Lung cancer risks in women with previous breast cancer. Eur J Cancer 2002;38:1520-1525.
6. Matesich SM, Shapiro CL. Second cancers after breast cancer treatment. Semin Oncol 2003;30:740-748.
7. Buiatti E, Crocetti E, Acciai S, et al. Incidence of second primary cancers in three Italian populationbased cancer registries. Eur J Cancer 1997;33:1829-1834.
8. Holdener EE, Osterwalder J, Senn HJ, et al. Secondary malignancies after breast cancer surgery. Comparison of retro-and prospective findings. Schweiz Med Wochenschr 1982;112:1800-1804.
9. Lee YN. Multipe malignant neoplasms in patients with breast carcinoma. Contemp Surg 1984;24:11-16.
10. Ford MB, Sigurdson AJ, Petrulis ES, et al. Effects of smoking and radiotherapy on lung carcinoma in breast carcinoma survivors. Cancer 2003;98:1457-1464.
11. Deutsch M, Land SR, Begovic M, et al. The incidence of lung carcinoma after surgery for breast carcinoma with and without postoperative radiotherapy. Results of National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trials B-04 and B-06. Cancer 2003;98:1362-1368.
12. Fowble B, Hanlon A, Freedman G, et al. Second cancers after conservative surgery and radiation for stages I-II breast cancer: identifying a subset of women at increased risk. Int J Radiat Oncol Biol Phys 2001;51:679-690.
13. Hill CA, North LB, Osborne BM. Bronchogenic carcinoma in breast carcinoma patients. AJR Am J Roentgenol 1983;140:259-264.
14. Cifuentes N, Pickren JW. Metastases from carcinoma of mammary gland: an autopsy study. J Surg Oncol 1979;11:193-205.
15. Lee YT. Breast carcinoma: pattern of metastasis at autopsy. J Surg Oncol 1983;23:175-180.
16. Borst MJ, Ingold JA. Metastatic patterns of invasive lobular versus invasive ductal carcinoma of the breast. Surgery 1993;114:637-641.
17. Kamby C, Vejborg I, Kristensen B, et al. Metastatic pattern in recurrent breast cancer. Special reference to intrathoracic recurrences. Cancer 1988;62:2226-2233.
18. Thomas JM, Redding WH, Sloane JP. The spread of breast cancer: importance of the intrathoracic lymphatic route and its relevance to treatment. Br J Cancer 1979;40:540-547.
19. Abrams HL, Spiro R, Goldstein N. Metastases in carcinoma; analysis of 1000 autopsied cases. Cancer 1950;3:74-85.
20. Kreisman H, Wolkove N, Finkelstein HS, et al. Breast cancer and thoracic metastases: review of 119 patients. Thorax 1983;38:175-179.
21. Casey JJ, Stempel BG, Scanlon EF, et al. The solitary pulmonary nodule in the patient with breast cancer. Surgery 1984;96:801-805.
22. Cahan WG, Castro EB. Significance of a solitary lung shadow in patients with breast cancer. Ann Surg 1975;181:137-143.
23. McDonald ML, Deschamps C, Ilstrup DM, et al. Pulmonary resection for metastatic breast cancer. Ann Thorac Surg 1994;58:1599-1602. (Pubitemid 24378963)
24. Shepherd MP. Endobronchial metastatic disease. Thorax 1982;37:362-365.
25. Adkins PC, Wesselhoeft Jr CW, Newman W, et al. Thoracotomy on the patient with previous malignancy: metastasis or new primary? J Thorac Cardiovasc Surg 1968;56:351-361.
26. Raab SS, Berg LC, Swanson PE, et al. Adenocarcinoma in the lung in patients with breast cancer. A prospective analysis of the discriminatory value of immunohistology. Am J Clin Pathol 1993;100:27-35.
27. Huvos AG, Lucas Jr JC, Foote Jr FW. Metaplastic breast carcinoma. Rare form of mammary cancer. NY State J Med 1973;73:1078-1082.
28. Fisher ER, Palekar AS, Gregorio RM, et al. Mucoepidermoid and squamous cell carcinomas of breast with reference to squamous metaplasia and giant cell tumors. Am J Surg Pathol 1983;7:15-27.
29. Ridolfi RL, Rosen PP, Port A, et al. Medullary carcinoma of the breast: a clinicopathologic study with 10 year follow-up. Cancer 1977;40:1365-1385.
30. Rosen PP. Carcinoma with metaplasia. In: Rosen PP (ed). Rosen's Breast Pathology 2nd edn. Lippincott Williams & Wilkins: Philadelphia, PA, 2001, pp 425-453.
31. Selvaggi SM, Kissner D, Qureshi F. Metastatic metaplastic carcinoma of the breast: diagnosis by bronchial brush cytology. Diagn Cytopathol 1989;5:396-399.
32. Tsukada Y, Fouad A, Pickren JW, et al. Central nervous system metastasis from breast carcinoma. Autopsy study. Cancer 1983;52:2349-2354.
33. Trillet V, Catajar JF, Croisile B, et al. Cerebral metastases as first symptom of bronchogenic carcinoma. A prospective study of 37 cases. Cancer 1991;67:2935-2940.
34. Bejarano PA, Baughman RP, Biddinger PW, et al. Surfactant proteins and thyroid transcription factor-1 in pulmonary and breast carcinomas. Mod Pathol 1996;9:445-452.
35. Harlamert HA, Mira J, Bejarano PA, et al. Thyroid transcription factor-1 and cytokeratins 7 and 20 in pulmonary and breast carcinoma. Acta Cytol 1998;42:1382-1388.
36. Kaufmann O, Deidesheimer T, Muehlenberg M, et al. Immunohistochemical differentiation of metastatic breast carcinomas from metastatic adenocarcinomas of other common primary sites. Histopathology 1996;29:233-240.
37. Zamecnik J, Kodet R. Value of thyroid transcription factor-1 and surfactant apoprotein A in the differential diagnosis of pulmonary carcinomas: a study of 109 cases. Virchows Arch 2002;440:353-361.
38. Yatabe Y, Mitsudomi T, Takahashi T. TTF-1 expression in pulmonary adenocarcinomas. Am J Surg Pathol 2002;26:767-773.
39. Kaufmann O, Dietel M. Thyroid transcription factor-1 is the superior immunohistochemical marker for pulmonary adenocarcinomas and large cell carcinomas compared to surfactant proteins A and B. Histopathology 2000;36:8-16.
40. Pelosi G, Fraggetta F, Pasini F, et al. Immunoreactivity for thyroid transcription factor-1 in stage I non-small cell carcinomas of the lung. Am J Surg Pathol 2001;25:363-372.
41. Tan D, Li Q, Deeb G, et al. Thyroid transcription factor-1 expression prevalence and its clinical implications in non-small cell lung cancer: a high-throughput tissue microarray and immunohistochemistry study. Hum Pathol 2003;34:597-604.
42. Rossi G, Murer B, Cavazza A, et al. Primary mucinous (so-called colloid) carcinomas of the lung: a clinicopathologic and immunohistochemical study with special reference to CDX-2 homeobox gene and MUC2 expression. Am J Surg Pathol 2004;28:442-452.
43. Mizutani Y, Nakajima T, Morinaga S, et al. Immunohistochemical localization of pulmonary surfactant apoproteins in various lung tumors. Special reference to nonmucus producing lung adenocarcinomas. Cancer 1988;61:532-537.
44. Whitsett JA, Glasser SW. Regulation of surfactant protein gene transcription. Biochim Biophys Acta 1998;1408:303-311.
45. Brasch F, Ochs M, Kahne T, et al. Involvement of napsin A in the C-and N-terminal processing of surfactant protein B in type-II pneumocytes of the human lung. J Biol Chem 2003;278:49006-49014.
46. Hirano T, Gong Y, Yoshida K, et al. Usefulness of TA02 (napsin A) to distinguish primary lung adenocarcinoma from metastatic lung adenocarcinoma. Lung Cancer 2003;41:155-162.
47. Suzuki A, Shijubo N, Yamada G, et al. Napsin A is useful to distinguish primary lung adenocarcinoma from adenocarcinomas of other organs. Pathol Res Pract 2005;201:579-586.
48. Canver CC, Memoli VA, Vanderveer PL, et al. Sex hormone receptors in non-small-cell lung cancer in human beings. J Thorac Cardiovasc Surg 1994;108:153-157.
49. Brown RW, Campagna LB, Dunn JK, et al. Immunohistochemical identification of tumor markers in metastatic adenocarcinoma. A diagnostic adjunct in the determination of primary site. Am J Clin Pathol 1997;107:12-19.
50. Ollayos CW, Riordan GP, Rushin JM. Estrogen receptor detection in paraffin sections of adenocarcinoma of the colon, pancreas, and lung. Arch Pathol Lab Med 1994;118:630-632.
51. di Nunno L, Larsson LG, Rinehart JJ, et al. Estrogen and progesterone receptors in non-small cell lung cancer in 248 consecutive patients who underwent surgical resection. Arch Pathol Lab Med 2000;124:1467-1470.
52. Lau SK, Chu PG, Weiss LM. Immunohistochemical expression of estrogen receptor in pulmonary adenocarcinoma. Appl Immunohistochem Mol Morphol 2006;14:83-87.
53. Kaufmann O, Kother S, Dietel M. Use of antibodies against estrogen and progesterone receptors to identify metastatic breast and ovarian carcinomas by conventional immunohistochemical and tyramide signal amplification methods. Mod Pathol 1998;11:357-363.
54. Radzikowska E, Langfort R, Giedronowicz D. Estrogen and progesterone receptors in non small cell lung cancer patients. Ann Thorac Cardiovasc Surg 2002;8:69-73.
55. Dabbs DJ, Landreneau RJ, Liu Y, et al. Detection of estrogen receptor by immunohistochemistry in pulmonary adenocarcinoma. Ann Thorac Surg 2002;73:403-405.
56. Wick MR, Lillemoe TJ, Copland GT, et al. Gross cystic disease fluid protein-15 as a marker for breast cancer: immunohistochemical analysis of 690 human neoplasms and comparison with alpha-lactalbumin. Hum Pathol 1989;20:281-287.
57. Bhargava R, Beriwal S, Dabbs DJ. Mammaglobin vs GCDFP-15: an immunohistologic validation survey for sensitivity and specificity. Am J Clin Pathol 2007;127:103-113.
58. Fritzsche FR, Thomas A, Winzer KJ, et al. Co-expression and prognostic value of gross cystic disease fluid protein 15 and mammaglobin in primary breast cancer. Histol Histopathol 2007;22:1221-1230.
59. Striebel JM, Dacic S, Yousem SA. Gross cystic disease fluid protein-(GCDFP-15) : expression in primary lung adenocarcinoma. Am J Surg Pathol 2008;32:426-432.
60. Wang LJ, Greaves WO, Sabo E, et al. GCDFP-15 positive and TTF-1 negative primary lung neoplasms: a tissue microarray study of 381 primary lung tumors. Appl Immunohistochem Mol Morphol 2009;17:505-511.
61. Takeda Y, Tsuta K, Shibuki Y, et al. Analysis of expression patterns of breast cancer-specific markers (mammaglobin and gross cystic disease fluid protein 15) in lung and pleural tumors. Arch Pathol Lab Med 2008;132:239-243.
62. Sasaki E, Tsunoda N, Hatanaka Y, et al. Breast-specific expression of MGB1/mammaglobin: an examination of 480 tumors from various organs and clinicopathological analysis of MGB1-positive breast cancers. Mod Pathol 2007;20:208-214.
63. Guan XF, Hamedani MK, Adeyinka A, et al. Relationship between mammaglobin expression and estrogen receptor status in breast tumors. Endocrine 2003;21:245-250.
64. Kouros-Mehr H, Kim JW, Bechis SK, et al. GATA-3 and the regulation of the mammary luminal cell fate. Curr Opin Cell Biol 2008;20:164-170.
65. Mehra R, Varambally S, Ding L, et al. Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis. Cancer Res 2005;65:11259-11264.
66. Ciocca V, Daskalakis C, Ciocca RM, et al. The significance of GATA3 expression in breast cancer: a 10-year follow-up study. Hum Pathol 2009;40:489-495.